Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday’s regular session. The company’s market…
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.
Aaron’s, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
U.S. stocks were mostly lower, with the Dow Jones index falling around 0.2% on Monday. Shares of The…
Mirum’s Volixibat Achieves Interim Analyses In VANTAGE PBC And VISTAS PSC Studies; Showed 3.8 Point Reduction From Baseline And 2.3 Point Placebo-Adjusted Reduction In Primary Endpoint Of Pruritus
- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus- VISTAS PSC interim analysis exceeds efficacy threshold for study
Mirum Pharmaceuticals Gets Positive CHMP Opinion For LIVMARLI Oral Solution For The Treatment Of PFIC In Patients 3-Months Or Older
Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo across all PFIC types studied.CHMP assessment
Reported Saturday, Mirum Pharmaceuticals’ LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
Presented by Professor Richard J. Thompson, MD, King's College London, United Kingdom
Patients with PFIC showed significant and sustained improvements in pruritus severity, serum bile acid (sBA) levels, total
Analyst Ratings For Mirum Pharmaceuticals
In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array…
Mirum Announces Publication Of Phase 3 MARCH Data In The Lancet Demonstrating Benefits Of LIVMARLI In patients With PFIC
- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied- Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and